These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11802333)

  • 1. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
    [No Abstract]   [Full Text] [Related]  

  • 3. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
    Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
    Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of rivastigmine in routine clinical practice.
    Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
    Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T
    Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
    González-Gutiérrez JL; Gobartt AL;
    Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.